香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 於其他海外監管市場發布的公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列中國同輻股份有限公司於 2025 年 8 月 2 1 日在上海證券交易所網站 ( http://www.sse.com.cn /)刊發的「中國同輻股份有限公司關於控股股東發生變更的 公告」，僅供參閱。 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 中國，北京，2025年8月21日 於本公告日期，董事會成員包括執行董事肖亞飛先生、張軍旗先生、霍穎穎女士 及馬曉宇女士；非執行董事陳贊先生、丁建民先生及常晉峪女士；及獨立非執行 董事潘昭國先生、陳景善女士、盧闖先生及安銳先生。 证券代码:1763.HK 债券代码:241820.SH 中国 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 內幕消息 控股股東無償劃轉股份完成過戶登記 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 本公告乃由中國同輻股份有限公司（「本公司」）根據香港聯合交易所有限公司（「聯 交所」）證券上市規則（「上市規則」）第13.09條及香港法例第571章證券及期貨條例 第XIVA部內幕消息條文（定義見上市規則）而作出。 茲提述本公司日期為2025年8月4日之公告（「該公告」），內容有關（其中包括）中 國寶原投資有限公司（「中國寶原」）擬將其持有的全部108,085,353股本公司內資股 （約佔本公司截至該公告日期全部已發行股本總額的33.79%）無償劃轉（「無償劃 轉」）予中國核工業集團有限公司（「中核集團」）。除本公告另有指明外，本公告所 用詞彙應與該公告所界定者具有相同涵義。 本公司於2025年8月21日接獲中國寳原轉發的中國證券登記結算有限責任公司出 具的《過戶登記確認 ...

Core Viewpoint - The medical radionuclide products market is experiencing significant growth, driven by advancements in precision medicine and the integration of diagnostic and therapeutic applications, with a projected compound annual growth rate (CAGR) of 19.16% from 2020 to 2024 and 9.23% from 2025 to 2031 [1][3]. Market Size and Forecast - In 2020, the global medical radionuclide products market was valued at $473.9 million, and it is expected to reach $955.2 million by 2024, indicating a CAGR of 19.16% during this period [1]. - By 2031, the market is projected to grow to $1.8932 billion, with a CAGR of 9.23% from 2025 to 2031 [1]. Industry Development Characteristics - The industry is evolving towards a dual focus on diagnosis and treatment, with new radiopharmaceuticals like ¹⁷⁷Lu and ²²³Ra leading the transition from diagnostic tools to core therapeutic methods [3]. - The trend of "Theranostics" is becoming prominent, promoting the paired use of diagnostic and therapeutic radionuclides to enhance accuracy and safety in treatment [3]. Favorable Factors for Industry Development - The growing demand for precision medicine is driving the need for targeted and effective treatment options, particularly in oncology [6]. - Technological advancements in nuclear imaging and radiation therapy, such as PET and SPECT, are providing a solid foundation for the development and application of medical radionuclide products [6]. - Increased government support through policies that facilitate faster approvals and funding for research is promoting industry growth [6]. - The high prevalence of diseases like cancer and cardiovascular conditions is creating a stable and expanding market for medical radionuclide products [6]. Unfavorable Factors for Industry Development - The complexity of production technology and high entry barriers due to the need for specialized knowledge in nuclear physics and radiochemistry limit market competition [8]. - The supply chain for key radionuclides is unstable, with production concentrated in a few countries, making it vulnerable to geopolitical and operational risks [8]. - Clinical promotion is hindered by strict radiation management regulations and a shortage of qualified professionals in nuclear medicine [8]. - The lengthy and complex regulatory approval processes for medical radionuclide products can delay market entry and affect profitability [8]. Barriers to Entry in the Industry - High technical barriers exist due to the need for interdisciplinary expertise in nuclear physics, radiochemistry, and pharmacology [10]. - Strict regulations governing the production and use of radionuclide products increase the complexity and cost of compliance [10]. - Significant investment is required for production equipment, such as nuclear reactors and cyclotrons, which raises the financial barrier for new entrants [10]. - The regulatory landscape is complicated by varying standards across countries, making international market entry challenging [10]. Talent Shortage - There is a notable shortage of specialized professionals in nuclear medicine, which affects the industry's ability to develop, produce, and promote medical radionuclide products effectively [11].

格隆汇8月14日丨中国同辐(01763.HK)公布，公司将于2025年8月28日召开董事会会议，以（其中包括） 审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布，以及审议派发中期股息的建议（如 有）。 ...

CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 董事長 肖亞飛 （於中華人民共和國註冊成立的股份有限公司） 承董事會命 中國同輻股份有限公司 （股份代號：1763） 董事會會議召開日期 中國同輻股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，董事會將於 2025年8月28日（星期四）舉行董事會會議，以考慮及通過（包括其他事項）本公司 及其附屬公司截至2025年6月30日止的六個月的中期業績及考慮派發中期股息。 中國，北京，2025年8月14日 於本公告日期，董事會成員包括執行董事肖亞飛先生、張軍旗先生、霍穎穎女士 及馬曉宇女士；非執行董事陳贊先生、丁建民先生及常晉峪女士；及獨立非執行 董事潘昭國先生、陳景善女士、盧闖先生及安銳先生。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 於其他海外監管市場發布的公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列中國同輻股份有限公司於 2025 年 8 月 6 日在上海證券交易所網站 ( http://www.sse.com.cn /)刊發的「中國同輻股份有限公司關於控股股東擬無償劃轉 股份的公告」，僅供參閱。 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 中國，北京，2025年8月6日 於本公告日期，董事會成員包括執行董事肖亞飛先生、張軍旗先生、霍穎穎女士 及馬曉宇女士；非執行董事陳贊先生、丁建民先生及常晉峪女士；及獨立非執行 董事潘昭國先生、陳景善女士、盧闖先生及安銳先生。 证券代码:1763.HK 债券代码:241820.SH 证券 ...

Core Viewpoint - The proposed transfer of shares from China Baoyuan Investment Co., Ltd. to China National Nuclear Corporation (CNNC) will enhance CNNC's direct control over China Tongfu (01763) and strengthen its position in the nuclear technology application industry [1][2]. Group 1: Share Transfer Details - China Baoyuan intends to transfer all of its 108 million domestic shares, representing approximately 33.79% of the total issued share capital, to CNNC [1]. - After the proposed transfer, CNNC will directly hold 108 million domestic shares (approximately 33.79% of the total issued share capital) and indirectly hold an additional 128 million domestic shares through various subsidiaries, totaling 236 million domestic shares, which is about 73.83% of the total issued share capital [1]. Group 2: Implications for the Company - Following the proposed transfer, China Baoyuan will no longer be a shareholder, while CNNC will remain the ultimate controlling shareholder of the company [2]. - CNNC's brand influence and industry background are expected to significantly enhance the company's position in technological innovation and market expansion, contributing to high-quality development [2]. - The company is anticipated to play a more critical role and assume greater responsibilities with the support of CNNC, thereby increasing its impact and core competitiveness in the industry [2].

Group 1 - The proposed transfer involves the transfer of 108 million domestic shares (approximately 33.79% of the total issued share capital) from China Baoyuan Investment Co., Ltd. to China National Nuclear Corporation (CNNC) [1][2] - After the proposed transfer, CNNC will directly hold 108 million domestic shares (approximately 33.79% of the total issued share capital) and indirectly hold an additional 128 million domestic shares (approximately 40.04% of the total issued share capital) through various subsidiaries, totaling 236 million domestic shares (approximately 73.83% of the total issued share capital) [1][2] Group 2 - Following the proposed transfer, China Baoyuan will no longer be a shareholder of the company, while CNNC will remain the ultimate controlling shareholder [2] - CNNC is positioned as a national leader in nuclear technology application, which is expected to enhance the company's status, influence, and core competitiveness in technology innovation and market expansion [2]

Core Viewpoint - China Tongfu (01763.HK) announced a proposed transfer of 108,085,353 domestic shares (approximately 33.79% of the total issued share capital) from its controlling shareholder, China Baoyuan Investment Co., Ltd., to its ultimate controlling shareholder, China National Nuclear Corporation (CNNC) [1] Group 1 - After the proposed transfer, CNNC will directly hold 108,085,353 domestic shares (approximately 33.79% of the total issued share capital) and will indirectly hold an additional 128,064,880 domestic shares through its subsidiaries, totaling 236,150,233 domestic shares, which represents approximately 73.83% of the total issued share capital post-transfer [1] - CNNC is recognized as a national leader in nuclear technology applications, and its brand influence and industry background are expected to significantly enhance the company's position, influence, and core competitiveness in technology innovation and market expansion [1] - The support from CNNC will enable the company to play a more critical role, undertake more significant responsibilities, and have a more pronounced impact in the industry [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 截至本公告日期，中核集團並未直接持有本公司股份，而是通過中國寶原、中 國原子能科學研究院（「原子能院」）、中國核動力研究設計院（「核動力院」）、北 京中核產業投資基金（有限合夥）（「中核基金」）及中核四〇四有限公司（「四〇四 公司」）間接持有本公司236,150,233股內資股，約佔本公司截至本公告日期全部 已發行股本總額的73.83%。擬議無償劃轉完成後，中核集團將直接持有本公司 108,085,353股內資股（約佔擬議無償劃轉完成後本公司全部已發行股本總額的 33.79%），並通過原子能院、核動力院、中核基金及四〇四公司間接持有本公司 128,064,880股內資股（約佔擬議無償劃轉完成後本公司全部已發行股本總額的 40.04%），即合計持有本公司236,150,233股內資股，約佔擬議無償劃轉完成後本 公司全部已發行股本總額的73.83%。 擬議無償劃轉完成後，中國寶原將不再是本公司的股東，而中核 ...